Industries

Exosome Therapeutics and Extracellular Vesicles

Name: Exosome Therapeutics and Extracellular Vesicles
Creator: Sell to Scientists

Exosome therapeutics harnesses extracellular vesicles—nano-sized lipid bilayer particles naturally secreted by cells—as both biomarkers and drug delivery vehicles, offering a biologically compatible alternative to synthetic lipid nanoparticles for nucleic acid and protein payloads. Codiak BioSciences, Evox Therapeutics, Anjarium Biosciences, and Capricor Therapeutics are advancing engineered exosome platforms through IND-enabling studies and early clinical trials, targeting oncology, neurodegeneration, and cardiovascular indications. Researchers procure ultracentrifugation systems, size-exclusion chromatography columns, nanoparticle tracking analysis instruments, electron microscopy grids for vesicle characterization, and GMP-grade cell culture media for exosome biomanufacturing. The field intersects RNA biology, synthetic biology, and advanced manufacturing, requiring specialized analytical tools including cryo-EM imaging and multi-parameter flow cytometry. Regulatory guidance on exosome characterization is evolving rapidly and Sell to Scientists CLI helps research teams identify compliant reagent suppliers, analytical CROs, and scale-up manufacturing partners for extracellular vesicle programs.

Details

Companies: Codiak BioSciencesEvox TherapeuticsAnjarium BiosciencesCapricor TherapeuticsCarmine TherapeuticsReNeuronExoCoBio
Market Size: $2.3 billion (2024), projected $9.4 billion by 2030 at 26.3% CAGR
Target Researchers: Cell biologists, vesicle biologists, drug delivery scientists, RNA therapeutics researchers, and regenerative medicine investigators studying natural nano-delivery vehicles.
Use Cases: Exosome-loaded siRNA and mRNA delivery to target tissuesExosome biomarker discovery in liquid biopsyStem-cell-derived exosomes for wound healing and neuroregenerationEngineered exosomes for CNS drug delivery across the blood-brain barrierPlant-derived nanovesicles as immunomodulatory agentsExosome-based vaccine adjuvant platformsGMP exosome manufacturing scale-up for clinical-grade production